Gunderson Dettmer represented client Overland Pharma in its joint venture with Allogene Therapeutics forming new company, Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.

In the announcement of the transaction, co-founder and chief medical officer of Overland Pharmaceuticals Hua Mu said, “Combined with Allogene’s domain expertise, this positions Allogene Overland Biopharm to bring these important new therapies to patients and physicians fighting cancer across Asia and around the world.”

The Gunderson deal team was led by Tim Ehrlich and included Peter Schoch, Stephen Wheeler and Kelvin Chan.